The CNS Market Outlook to 2012

CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer’s and Parkinson’s disease. ‘The CNS Market Outlook to 2012’ is a new report published by Business Insights that provides a detailed epidemiological analysis of major indications within the CNS disorders market, and examines the factors impacting their prevalence. The current opportunities and threats facing the market are assessed and the most promising potential growth areas across all indications are highlighted. The report also profiles the key trends influencing treatment sales and analyses the competitive dynamics of leading brands within each indication. Discover the key trends and growth drivers within the CNS market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report...

About the Author: Revati Nehru

Revati Nehru is an independent healthcare analyst with four years’ experience in pharmaceutical research and advisory services. Her core focuses is on major therapy areas including CNS and cardiovascular disorders, and women’s health. Revati holds a Master’s degree in International Healthcare Management, Economics and Policy from SDA Bocconi, Milan.

Published: October 2007 - Global.
Table of Contents
Table of Contents (PDF)
Price: $2,875.00 / GBP1,437.50